Bevacizumab-IRDye800CW (University Hospital Groningen)

N/A

Report date: 2025/01/02 16:12:07

Base Information

Drug NameBevacizumab-IRDye800CW (University Hospital Groningen)
Drug Alias NameBevacizumab-800CW
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsMacular DegenerationBarrett EsophagusThyroid Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Hospital Groningen
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center Groningen
Inactive CompaniesN/A
Active IndicationsMacular DegenerationThyroid NeoplasmsPituitary Neoplasms +[4] 
Inactive IndicationsBarrett EsophagusPapilloma, InvertedSarcoma

Other Information

ATC CodeN/A
Related LinksN/A